Immunovant
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Immunovant generated cash of -$214,227,000, which is less than the previous year. Cash used in financing activities reached the amount of $472,427,000 last year. Net change in cash is therefore $258,833,000.
Cash Flow
| 2019 | -28.54M | -52K | 35.58M |
|---|---|---|---|
| 2020 | -53.35M | -31K | 146.97M |
| 2021 | -83.32M | -210K | 383.11M |
| 2022 | -106.11M | -254K | 200.12M |
| 2023 | -188.19M | -197K | 70.88M |
| 2024 | -214.22M | -360K | 472.42M |
IMVT Cash Flow Statement (2019 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 376.53M | 493.81M | 400.14M | 100.57M | 6.98M | 0 |
Operating activities | ||||||
Net income | -259.33M | -210.96M | -156.73M | -107.43M | -66.38M | -28.59M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 231K | 193K | 126K | 65K | 21K | 10K |
Stock-based compensation expense | 41.11M | 32.29M | 34.24M | 18.82M | 6.96M | 1.30M |
| Deferred income tax benefit | 41.11M | 32.29M | 34.24M | 18.82M | 6.96M | 1.30M |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | -4.55M | 11.76M | -11.63M | -596K | -83K | 0 |
Inventories | 0 | 0 | 0 | 596K | 83K | 0 |
Accounts payable | 5.78M | -17.12M | 16.25M | 1.25M | 967K | 0 |
Cash generated by operating activities | -214.22M | -188.19M | -106.11M | -83.32M | -53.35M | -28.54M |
Investing activities | ||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -360K | -197K | -254K | -210K | -31K | -52K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -360K | -197K | -254K | -210K | -31K | -52K |
Financing activities | ||||||
Common Stock Issued | 472.74M | 70.5M | 129K | 319.78M | -1.95M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -3.19M | -5M | 0 |
Cash used in financing activities | 472.42M | 70.88M | 200.12M | 383.11M | 146.97M | 35.58M |
Net Change In Cash | 258.83M | -117.28M | 93.67M | 299.57M | 93.58M | 6.98M |
Cash at end of period | 635.36M | 376.53M | 493.81M | 400.14M | 100.57M | 6.98M |
| Data source | Data source | Data source | Data source | Data source |